Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2023-06-09 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
第二届董事会第二十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Shenzhen Microchip Biotechnology Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references to other announcements on the Shanghai Stock Exchange website. The content focuses on board decisions such as introducing external investors, implementing equity incentives, registering branch offices, and scheduling an extraordinary general meeting. There are no financial statements, earnings data, or detailed financial analysis present. The document is not a full report but a meeting resolution announcement. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2023-06-09 Chinese
关于微芯新域增资扩股并引入外部投资者的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a capital increase and introduction of an external investor into a subsidiary company, detailing the transaction, governance changes, and financial impacts. It includes specifics about shareholding changes, investment amounts, board composition, and legal opinions. The document is not a full financial report but a corporate announcement about financing and capital structure changes. It does not contain comprehensive financial statements or quarterly/yearly results but focuses on a financing event and related governance implications. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (5751 characters) and detailed transaction description support this classification with high confidence.
2023-06-09 Chinese
安信证券股份有限公司关于深圳微芯生物科技股份有限公司子公司实施股权激励暨关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed report from a sponsoring securities company (安信证券股份有限公司) regarding the implementation of an equity incentive plan by a subsidiary (成都微芯新域生物技术有限公司) of 深圳微芯生物科技股份有限公司. It includes descriptions of the related party transactions, approvals by the board and supervisory committee, independent directors' opinions, and the sponsor's verification opinion. The document is focused on the equity incentive plan and related party transaction review, not on financial results, earnings, or annual reporting. It is not a short announcement or a certification letter but a substantive report on a specific corporate governance and related transaction matter. This fits best under the category of Regulatory Filings (RNS) as it is a regulatory disclosure about a related party transaction and equity incentive plan, not a full financial report or other specific category. The document length is 3641 characters, which is relatively short but contains detailed content, so it is not a mere announcement (RPA). Therefore, the classification is RNS with high confidence.
2023-06-09 Chinese
2022年深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券2023年跟踪评级报告
Audit Report / Information Classification · 95% confidence The document is a detailed credit rating report issued by CSCI Pengyuan Credit Rating Agency for Shenzhen Microcore Biotech Co., Ltd. regarding its convertible bonds issued in 2022 and the 2023 follow-up rating. It includes extensive financial data, company background, industry environment, policy analysis, and credit rating methodology. The document is not an annual or interim financial report, nor is it an earnings release or management discussion. It is a standalone credit rating report focused on the creditworthiness and risk assessment of the company's bonds. This fits the category of an Audit Report / Information (AR), which includes standalone audit or credit rating reports and related financial assessments. The document length (15,000 characters) and content confirm it is the full report, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-06-05 Chinese
关于“微芯转债”跟踪信用评级结果的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the tracking credit rating results of a convertible bond issued by Shenzhen Microchip Biotechnology Co., Ltd. It includes details about the previous and current credit ratings, the rating agency, and the date of the rating report. The document is relatively short (878 characters) and serves as a formal announcement of the credit rating update rather than a full financial report or detailed analysis. It does not contain financial statements or comprehensive financial data. Therefore, it fits best into the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit into more specific categories.
2023-06-05 Chinese
2022年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2022 Annual General Meeting Resolution Announcement" from Shenzhen Microchip Biotechnology Co., Ltd. It details the date and location of the AGM, attendance, voting results on various proposals including the 2022 annual reports, financial statements, profit distribution, director remuneration, and auditor appointment. It also includes legal witness statements confirming the legality and validity of the meeting and voting process. The document is a formal announcement of the resolutions passed at the AGM, including voting results, rather than the full annual report or financial statements themselves. The document length is 3684 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-05-17 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.